Zymic Technology (ZYMIQ) Q4 2025 earnings summary

Executive summary

• Achieved 48% year-over-year net sales growth to SEK 1,902 thousand, driven by fjör and Kalzyme brands.

• Strategic recruitment in sales, marketing, and biopharma to prepare for 2026 expansion.

• Production of enzyme tablets relocated to Sweden, meeting cost targets and scalability.

• Strengthened commercial structure and signed new agreements in Asia and Europe.

• IPO preparations ongoing, with a directed share issue planned to close in April 2026.

Financial highlights

• Net sales for 2025: SEK 1,902 thousand (up 48% from SEK 1,281 thousand in 2024).

• Loss after tax for 2025: SEK -12,167 thousand (2024: SEK -10,954 thousand).

• Q4 2025 net sales: SEK 356 thousand (Q4 2024: SEK 269 thousand).

• Q4 2025 loss after tax: SEK -5,925 thousand (Q4 2024: SEK -2,610 thousand).

• Cash and cash equivalents at year-end: SEK 2,488 thousand (2024: SEK 3,189 thousand).

Outlook and guidance

• Positioned for growth, increased revenues, and international expansion in 2026.

• Several R&D studies to be published in 2026, expected to drive industry and partner interest.

• Ongoing IPO process with focus shifting back to listing after share issue completion.